HK40036028A - Inhibitors of mutant egfr family tyrosine-kinases - Google Patents

Description

Inhibitors of mutant EGFR family tyrosine kinases

Technical Field

The present disclosure relates generally to inhibitors of mutant Epidermal Growth Factor Receptor (EGFR) family tyrosine kinases, pharmaceutically acceptable salts or solvates thereof, and pharmaceutical compositions comprising an EGFR family tyrosine kinase inhibitor, a salt or solvate thereof as an active ingredient. More specifically, the present disclosure relates to EGFR family tyrosine kinase inhibitors that are selective for the C797S mutation in EGFR and/or the C805S mutation in HER2, which are effective in inhibiting the growth of cancer cells induced by overexpression or activation of the EGFR family tyrosine kinase.

Background

There are many signal transduction systems in cells that are functionally linked to control cell proliferation, growth, metastasis and apoptosis. Disruption of intracellular control systems by genetic and environmental factors can lead to abnormal expansion or disruption of signal transduction systems, resulting in the production of tumor cells.

Protein tyrosine kinases play an important role in this cellular regulation, and their abnormal expression or mutation is observed in cancer cells. Protein tyrosine kinase is an enzyme that catalyzes the transport of phosphate from ATP to tyrosine located on protein substrates. Many growth factor receptor proteins function as tyrosine kinases to transmit cellular signals. The interaction between growth factors and their receptors can generally control cell growth, but aberrant signal transduction caused by mutation or overexpression of any receptor will often induce tumor cells and cancer.

Protein tyrosine kinases have been classified into many families according to their growth factor types, and particularly tyrosine kinases structurally related to the Epidermal Growth Factor Receptor (EGFR) have been intensively studied. EGFR tyrosine kinase consists of a receptor and a tyrosine kinase, and transmits extracellular signals to the nucleus through the cell membrane. The EGF receptor tyrosine kinase family includes EGFR (Erb-B1), HER2(Erb-B2), HER3(Erb-B3), and Erb-B4, each of which may form a homodimeric or heterodimeric signaling complex. Also, overexpression of more than one such heterodimer is often observed in malignant cells. In addition, both EGFR and HER2 are known to significantly promote the formation of heterodimer-signaling complexes.

For example, activating mutations in the EGFR kinase domain are observed in about 10-20% of non-small cell lung cancers (NSCLCs). EGFR tyrosine kinase inhibitors (EGFR-TKI) have been developed for targeting mutated EGFR. EGFR-TKI binds reversibly or irreversibly to the ATP-binding pocket of EGFR and inhibits phosphorylation of EGFR, thereby inhibiting activation of the EGFR signaling pathway.

Several small molecule drugs (e.g., d746-750 mutation, L8585R mutation, and exon 20 insertion mutation) have been developed for inhibiting activated mutant EGFR family tyrosine kinases, e.g., gefitinib, erlotinib, lapatinib, and the like. Gefitinib or erlotinib selectively and reversibly inhibits EGFR and lapatinib reversibly inhibits EGFR and HER2, thereby inhibiting tumor growth, thereby significantly extending patient life or providing therapeutic advantages.

The foregoing small molecule inhibitors of EGFR tyrosine kinase share common structural features of the quinazoline moiety, and tyrosine kinase inhibitors having a quinazoline moiety have been described in international publications WO 99/006396, WO 99/006378, WO 97/038983, WO2000/031048, WO 98/050038, WO 99/024037, WO 2000/006555, WO 2001/098277, WO 2003/045939, WO 2003/049740 and WO 2001/012290; U.S. Pat. Nos. 7,019,012 and 6,225,318; and european patent nos. 0787722, 0387063 and 1292591.

Irreversible inhibitors against EGFR targets have been found to be more advantageous in overcoming the problem of drug resistance development than conventional reversible inhibitors. Irreversible inhibitors have been developed, such as BIBW-2992(British journal Cancer 98,80,2008), HKI-272(Cancer Research 64,3958,2004), and AV-412(Cancer Sci.98(12),1977,2007). The common feature of the above irreversible inhibitors is an acrylamide functionality at the C-6 position of the quinazoline or cyanoquinazoline residue, which forms a covalent bond with cysteine 797(Cys797, formerly Cys773) located in the ATP domain of EGFR or cysteine 805(Cys805) of HER2, thereby irreversibly blocking autophosphorylation of EGFR or HER2 and effectively inhibiting cancer cell signaling. These irreversible inhibitors exhibit higher in vitro and in vivo inhibitory activity compared to conventional reversible inhibitors.

International patent publication WO 2008/032039 discloses a novel anti-cancer compound having another acrylamide substituent at the C-6 position of quinazoline, which shows improved inhibitory activity against EGFR tyrosine kinase.

These drugs have shown superior clinical efficacy, with objective responses, improved progression-free survival and quality of life in about 70% of patients compared to simple chemotherapy. However, resistance occurs in non-small cell lung cancer patients who respond well to primary treatment. This acquired resistance is due to somatic mutations secondary to the conserved position (T790M) (e.g., L8585R/T790M, d746-750/T790M mutation, exon 20 insertion/T790M mutation). About half of the patients treated with gefitinib or erlotinib develop resistance to gefitinib or erlotinib, and such drugs have no substantial clinical effect on such EGFR T790M variant patients. The T790M mutation blocks binding of EGFR inhibitors to the ATP binding site of EGFR.

Second generation EGFR inhibitors, such as afatinib, dacatinib, bositinib, and lenatinib, although developed to overcome acquired resistance, cause a variety of serious side effects due to simultaneous inhibition of wild-type EGFR. The small molecule inhibitor forms a covalent bond with a cysteine residue at position 797(Cys797) in EGFR or cysteine 805 of HER2, thereby irreversibly blocking autophosphorylation of EGFR or HER2 and effectively inhibiting signal transfer in cancer cells.

Several irreversible second generation EGFR inhibitors are described in international publication No. WO 2008/150118, which is incorporated herein by reference in its entirety. A common feature of the above irreversible inhibitors is an acrylamide functionality on the aniline-quinazoline backbone, wherein a spacer is located between the acrylamide functionality and the quinazoline ring. The acrylamide functionality forms covalent bonds with cysteine 797(Cys797) and cysteine 805(Cys805) located in the ATP domains of EGFR and HER2, respectively.

Third-generation EGFR inhibitors, including azatinib, osetinib (described in U.S. Pat. No.8,956,235), rocatinib, HM61713 and WZ₄002 exhibited characteristic specificity for the drug resistant T790M mutation. A common feature of the aforementioned irreversible inhibitors is the acrylamide functionality on the pyrimidine scaffold.

About 10-12% of EGFR mutant NSCLC patients are inserted within the EGFR exon 20 in-frame and are generally resistant to EGFR-TKI. Furthermore, 90% of HER2 mutations in NSCLC are exon 20 mutations. Available tyrosine kinase inhibitors of HER2 (afatinib, lapatinib, naratinib) have limited activity in patients with EGFR/HER2 exon 20 mutations. Third generation EGFR TKI (ocitinib and rociletinib) was found to have minimal activity in patient derived EGFR exon 20 driven NSCLC xenograft models. Similar to EGFR, activated HER2 may undergo a secondary mutation at the gatekeeper position (T798M), resulting in resistance to tyrosine kinase inhibitors of activated HER 2.

The emergence of EGFR (C797S) and HER2(C805S) mutations has led to new resistance to all known third generation EGRF-TKIs by preventing these irreversible inhibitors from forming covalent bonds with the side chains of EGFR C797 or HER2C 805.

Summary of The Invention

One aspect of the present disclosure provides an Epidermal Growth Factor Receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to serine residue S797 in EGFR with a C797S mutation or serine residue S805 in HER2 with a C805S mutation. Patients with T790M, T798M, and/or exon 20 insertion mutations treated with irreversible inhibitors may develop resistance by acquiring a C797S mutation in EGFR and/or a C805S mutation in HER 2. The inhibitors of the present disclosure are not hindered by the T790M or T798M mutations, and may advantageously bind to the C797S and/or C805S mutated serine to block autophosphorylation of EGFR and/or HER2 and inhibit signal transfer by cancer cells. As used herein, unless otherwise specified, "EGFR family tyrosine kinase inhibitor" or "EGFR tyrosine kinase inhibitor" refers to small molecule compounds that inhibit EGFR family tyrosine kinase mutations (e.g., d746-750 mutations, L85 8585R mutations, and/or EGFR or HER2 exon 20 insertion mutations) and secondary or tertiary mutations thereof (e.g., T790M mutations, T798M mutations, C797S mutations, and C805S mutations).

As used herein and unless otherwise indicated, an EGFR tyrosine kinase inhibitor is "selective" if it cannot simultaneously substantially inhibit wild-type EGFR.

As used herein, an inhibitor may "bind" to a serine residue if the inhibitor can form a coordinate or covalent bond with the serine residue, unless otherwise specified.

Another aspect of the present disclosure provides an EGFR family tyrosine kinase inhibitor comprising a functional group that can bind to serine mutant C797S EGFR and/or C805S mutant HER2, wherein the EGFR family tyrosine kinase inhibitor comprises a compound of formula (I):

wherein

A is

R₄Each independently is hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, heteroaryl, or together form a cycloalkyl;

R₅is-NHR 6, -C (O) R7, alkyl, cycloalkyl, perfluoroalkyl, aryl or heteroaryl;

R₆is hydrogen, alkyl, cycloalkyl, perhaloalkyl, aryl or heteroaryl; and R7 is NHR6, hydrogen, alkyl, cycloalkyl, perhaloalkyl, aryl or heteroaryl;

R₁₁each independently selected from hydrogen, alkyl-CO 2R12, or can form together (═ O), and R12 is selected from hydrogen or C1-6 alkyl;

R₁is C substituted by 1 to 5X_6-10Aryl, 5-to 10-membered heterocyclic group having at least one selected from N, O and S and substituted with 1 to 5X, or C substituted with phenyl_1-6An alkyl group;

R₂is hydrogen, hydroxy, C_1-6Alkoxy or by C_1-6Alkoxy or C substituted with at least one 5-or 6-membered heterocyclyl selected from N, O and S_1-6An alkoxy group;

R₃is hydrogen, -COOH, C_1-6Alkoxycarbonyl, N-unsubstituted or N-acylamino substituted by Y;

n_aand n_bAre all integers from 0 to 6, with the proviso that n_aAnd n_bNot simultaneously 0, and when n_aIs 0, said

Is that

And when n is_bIs 0, saidIs that

Wherein

X is hydrogen, halogen, hydroxy, cyano, nitro, (mono-, di-or trihalo) methyl, mercapto, C_1-6Alkylthio, acrylamido, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Alkoxy, aryloxy, C_1-6Dialkylamino, C substituted by Z_1-6Alkyl or C substituted by Z_1-6An alkoxy group;

y is hydroxy, or C_1-6Alkyl, or C substituted by Z_1-6An alkyl group; and

z is hydroxy, C_1-3Alkoxy radical, C_1-3Alkylthio radical, C_1-3Alkylsulfonyl, di-C_1-3Alkylamine, C_1-6Alkyl, aryl, or 5-or 6-membered aromatic or non-aromatic heterocyclic group containing 1 to 4 members selected from N, O, S, SO and SO₂And said aryl and heterocyclyl are unsubstituted or selected from halogen, hydroxy, amino, nitro, cyano, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Alkoxy radical, C_1-6Monoalkylamino and C_1-6A substituent of a dialkylamino group.

Another aspect of the present disclosure provides an EGFR tyrosine kinase inhibitor comprising a functional group that can bind to the serine mutations C797S EGFR or C805S HER2, wherein the EGFR tyrosine kinase inhibitor comprises a compound of formula (II):

wherein

A is

E is

J comprises-CO₂R₁₀Halogen, NHC (O) R₁₀；

R₈Each independently selected from hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, heteroaryl or together form a cycloalkyl;

R₁₀including hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, or heteroaryl;

R₁₁each independently selected from hydrogen, alkyl-CO₂R₁₂Or can form together (═ O), and R₁₂Selected from hydrogen or C_1-6An alkyl group;

c and D are each independently selected from alkyl, -N (R)₈)₂、-OR₈alkyl-W or together can comprise cycloalkyl;

w is selected from-N (R)₈)₂OR-OR₈(ii) a And

l is selected from-CO₂NH₂,-CO₂NHR₁₀Alkyl, perfluoroalkyl, or cycloalkyl.

Another aspect of the present disclosure provides an EGFR family tyrosine kinase inhibitor comprising a functional group that can bind to serine mutations C797S EGFR and/or C805S HER2, wherein the EGFR family tyrosine kinase inhibitor comprises a compound of formula (III):

wherein

G is:

R₉each independently selected from hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, heteroaryl or together form a cycloalkyl;

m is selected from-CO₂NH₂、-CO₂NHR₁₀Alkyl, perfluoroalkyl, or cycloalkyl, optionally containing alkyl branches on one or more carbon atoms;

R₁₀including hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, or heteroaryl; and

R₁₁each independently selected from hydrogen, alkyl-CO₂R₁₂Or can form together (═ O), and R₁₂Selected from hydrogen or C_1-6An alkyl group.

Another aspect of the present disclosure provides a pharmaceutical composition comprising an EGFR tyrosine kinase inhibitor comprising a functional group or a pharmaceutically acceptable salt or solvate thereof that can bind to the serine mutation (C797S) and/or (C805S) of HER2 of EGFR as an active ingredient and a pharmaceutically acceptable carrier.

Another aspect of the disclosure provides a method of treating a subject having an EGFR C797S mutation or a HER2C805S mutation, comprising administering to the subject a pharmaceutically effective amount of an EGFR family tyrosine kinase compound according to the disclosure, or a pharmaceutically acceptable salt or solvate thereof.

For the compounds and compositions described herein, it is contemplated that optional features are selected from the various aspects, embodiments, and examples provided herein.

Further aspects and advantages will be apparent to those of ordinary skill in the art from a reading of the following detailed description. While the compounds and compositions are susceptible of embodiments in various forms, the following description includes specific embodiments, with the understanding that the disclosure is illustrative, and is not intended to limit the invention to the specific embodiments described herein.

Detailed Description

The present disclosure provides an Epidermal Growth Factor Receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to serine residue S797 in EGFR with a C797S mutation and/or serine residue S805 in HER2 with a C805S mutation. Advantageously, EGFR tyrosine kinase inhibitors comprising a functional group that can bind to serine in the C797S mutation of EGFR and/or the C805S mutation of HER2 also selectively inhibit the mutations T790M/C797S EGFR and/or T798M/C805 HER2, provided that the C797S and/or C805S mutations co-exist with the T790M mutation or the T798M mutation, respectively. Without being bound by theory, it is believed that mutations in EGFR involve the replacement of cysteine 797 with serine, whereas mutations in HER2 involve the replacement of cysteine 805 with serine, and that the nucleophilic hydroxyl group of serine can bind to electron deficient functional groups (e.g., boronic acid or electron deficient carbonyl) on EGFR tyrosine kinase inhibitors. The electron-deficient carbonyl group can act as a serine trap, thereby disrupting the proliferation signal of the protein through bond formation.

The EGFR family tyrosine kinase inhibitor comprising a functional group that can bind to serine in the C797S mutation of EGFR and/or the C805S mutation of HER2 may comprise a compound of formula (I) or a pharmaceutically acceptable salt or solvate:

wherein

A is

R₄Each independently is hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, heteroaryl, or together form a cycloalkyl;

R₅is-NHR₆,-C(O)R₇Alkyl, cycloalkyl, perfluoroalkyl, aryl or heteroaryl;

R₆is hydrogen, alkyl, cycloalkyl, perhaloalkyl, aryl or heteroaryl; and R is₇Is NHR₆Hydrogen, alkyl, cycloalkyl, perhaloalkyl, aryl or heteroaryl;

R₁₁each independently selected from hydrogen, alkyl-CO₂R₁₂Or can form together (═ O), and R₁₂Selected from hydrogen or C_1-6An alkyl group;

R₁is C substituted by 1 to 5X_6-10Aryl, 5-to 10-membered heterocyclic group having at least one selected from N, O and S and substituted with 1 to 5X, or C substituted with phenyl_1-6An alkyl group;

R₂is hydrogen, hydroxy, C_1-6Alkoxy or by C_1-6Alkoxy or C substituted with at least one 5-or 6-membered heterocyclyl selected from N, O and S_1-6An alkoxy group;

R₃is hydrogen, -COOH, C_1-6Alkoxycarbonyl, N-unsubstituted or N-acylamino substituted by Y;

n_aand n_bAre all integers from 0 to 6, with the proviso that n_aAnd n_bWhen the temperature is not 0 at the same time,

and when n is_aIs 0, saidIs that

And when n is_bIs 0, saidIs that

Wherein

X is hydrogen, halogen, hydroxy, cyano, nitro, (mono-, di-or trihalo) methyl, mercapto, C_1-6Alkylthio, acrylamido, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Alkoxy, aryloxy, C_1-6Dialkylamino, C substituted by Z_1-6Alkyl or C substituted by Z_1-6An alkoxy group;

y is hydroxy, or C_1-6Alkyl, or C substituted by Z_1-6An alkyl group; and

z is hydroxy, C_1-3Alkoxy radical, C_1-3Alkylthio radical, C_1-3Alkylsulfonyl, di-C_1-3Alkylamine, C_1-6Alkyl, aryl, or 5-or 6-membered aromatic or non-aromatic heterocyclic group containing 1 to 4 members selected from N, O, S, SO and SO₂And said aryl and heterocyclyl are unsubstituted or selected from halogen, hydroxy, amino, nitro, cyano, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Alkoxy radical, C_1-6Monoalkylamino and C_1-6A substituent of a dialkylamino group.

The term "halogen" means fluorine, chlorine, bromine or iodine unless otherwise specified. In embodiments, each halogen may be individually selected from fluorine, chlorine, bromine, or iodine. In embodiments, the at least one halogen comprises fluorine. In embodiments, all halogens comprise fluorine. In embodiments, the at least one halogen comprises chlorine.

Unless otherwise specified, the term "alkyl" refers to a saturated monovalent hydrocarbon radical having a straight, cyclic, or branched moiety (i.e., which may be unsubstituted or substituted). In embodiments, each alkyl group may be independently selected from unsubstituted alkyl groups and alkyl groups substituted with methyl, ethyl, propyl, or substituents thereof.

In embodiments, where X is aryloxy, X may be phenoxy. In embodiments, wherein Y is C_1-6Alkyl or C substituted by Z_1-6Alkyl radical, said C_1-6The alkyl group may contain 1 to 4 groups selected from N, O, S, SO and SO₂Part (c) of (a). In embodiments, where Z is aryl, Z may be phenyl. In embodiments, wherein Z is aryl, the aryl may be one comprising 1-4 substituents selected from N, O, S, SO and SO₂C of (a)_5-12A monocyclic or bicyclic aromatic or nonaromatic group.

In embodiments, R₆Is C_1-6Alkyl or C_3-7A cycloalkyl group. In embodiments, R₇Is C_1-6Alkyl or C_3-7A cycloalkyl group. In embodiments, R₁Is C substituted by 3X₆-an aryl group. In an embodiment, n_aAnd n_bAre both 2. In embodiments, R₂Is methoxy. In embodiments, R₃Is hydrogen.

In embodiments, A isIn embodiments, A isAnd R is₄Are all halogens. In embodiments, A isAnd R is₄Are both fluorine.

In embodiments, A isR₅is-C (O) R₇，R₇Is C_1-6Alkyl or C_3-7Cycloalkyl radical, R₁Is C substituted by 3X₆Aryl radical, n_aAnd n_bAre both 2, R₂Is methoxy, R₃Is hydrogen, R₄Are each individually halogen.

In embodiments, A isR₅Comprising C (O) R₇And R is₇Comprising NHR₆. In embodiments, A isR₅Comprising C (O) R₇，R₇Comprising NHR₆，R₄Each independently selected from fluorine and C_1-6Alkyl radical, C_3-7Cycloalkyl groups or together form a cycloalkyl group. In embodiments, A isR₅Comprising C (O) R₇，R₇Comprising NHR6, R₆Selected from hydrogen, C_1-6Alkyl radical, C_3-7Cycloalkyl, perhaloalkyl, aryl and heteroaryl.

In embodiments, A isR₅Comprising C (O) R₇，R₇Comprising NHR₆、C_1-6Alkyl or C_3-7Cycloalkyl radical, R₆Selected from hydrogen, C_1-6Alkyl radical, C_3-7Cycloalkyl, perhaloalkyl, aryl and heteroaryl, R₄Each independently selected from fluorine and C_1-6Alkyl radical, C_3-7Cycloalkyl or together form cycloalkyl, R₁Is C substituted by 3X₆Aryl radical, n_aAnd n_bAre both 2, R₂Is methoxy, R₃Is hydrogen.

In embodiments, A isIn embodiments, A isAnd R is₄Each independently of the others is hydrogen, halogen, C_1-6Alkyl radical, C_3-7Cycloalkyl, perfluoroalkyl, cycloalkyl, aryl, heteroaryl or together form C_3-7A cycloalkyl group. In embodiments, A isR₄Each independently of the others is hydrogen, halogen, C_1-6Alkyl radical, C_3-7Cycloalkyl, perfluoroalkyl, cycloalkyl, aryl, heteroaryl or together form C_3-7Cycloalkyl radical, R₁Is C substituted by 3X₆Aryl radical, n_aAnd n_bAre both 2, R₂Is methoxy, and R₃Is hydrogen.

In embodiments, A isIn embodiments, A isWherein two R are₁₁Together include (═ O), two R₁₁Each comprising methyl-CO₂R₁₂Wherein R is₁₂Is hydrogen such that A isIn embodiments, A isFor exampleAnd R is₄Each independently of the others is hydrogen, halogen, C_1-6Alkyl radical, C_3-7Cycloalkyl, perfluoroalkyl, cycloalkyl, aryl, heteroaryl or together form C_3-7A cycloalkyl group.

In embodiments, A isFor exampleR₄Each independently of the others is hydrogen, halogen, C_1-6Alkyl radical, C_3-7Cycloalkyl, perfluoroalkyl, cycloalkyl, aryl, heteroaryl or together form C_3-7Cycloalkyl radical, R₁Is C substituted by 3X₆Aryl radical, n_aAnd n_bAre both 2, R₂Is methoxy, and R₃Is hydrogen.

Examples of compounds of formula (I) according to the invention include:

1)4- (4- ((4- (3, 4-dichloro-2-fluorophenyl) amino) -7-methoxyquinazolin-6-yl) oxy) piperidin-1-yl) -N,3, 3-trimethyl-2, 4-dioxobutanamide;

2) (2- (4- ((4- ((3, 4-dichloro-2-fluorophenyl) amino) -7-methoxyquinazolin-6-yl) oxy) piperidin-1-yl) -2-oxoethyl) boronic acid; and

3)1- (4- ((4- ((3, 4-dichloro-2-fluorophenyl) amino) -7-methoxyquinazolin-6-yl) oxy) piperidin-1-yl) -2, 2-difluorobutane-1, 3-dione.

Another aspect of the present disclosure provides an EGFR family tyrosine kinase inhibitor comprising a functional group that can bind to serine in C797S of EGFR and/or serine in C805S of HER2, wherein the EGFR family inhibitor comprises a compound of formula (II):

wherein the content of the first and second substances,

a is

E is

J comprises-CO₂R₁₀Halogen, NHC (O) R₁₀；

R₈Each independently selected from hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, heteroaryl or together form a cycloalkyl;

R₁₀including hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, or heteroaryl;

R₁₁each independently selected from hydrogen, alkyl-CO₂R₁₂Or can form together (═ O), and R₁₂Selected from hydrogen or C_1-6An alkyl group;

c and D are each independently selected from alkyl, -N (R)₈)₂、-OR₈alkyl-W or together can comprise cycloalkyl;

w is selected from-N (R)₈)₂OR-OR₈(ii) a And

l is selected from-CO₂NH₂、-CO₂NHR₁₀Alkyl, perFluoroalkyl or cycloalkyl.

In embodiments, J comprises halogen. In embodiments, J comprises chlorine. In embodiments, J comprises-NHC (O) R₁₀And R is₁₀Comprises C_1-6Alkyl or C_3-7Cycloalkyl, optionally substituted C_1-6Alkyl or C_3-7A cycloalkyl group. In embodiments, J comprises-CO₂R₁₀And R is₁₀Comprises C_1-6Alkyl or C_3-7Cycloalkyl, optionally substituted C_1-6Alkyl or C_3-7A cycloalkyl group. In embodiments, J comprises-CO₂R₁₀And R is₁₀Including t-butyl or cyclohexyl or J-NHC (O) R₁₀And R is₁₀Including isopropyl.

In embodiments, one or both of C and D is substituted with C on one or more carbon atoms_1-3Alkyl substitution. In embodiments, L is C_1-8Alkyl or C_3-7Cycloalkyl and unsubstituted or substituted on one or more carbon atoms by C_1-3Alkyl substitution. In embodiments, R₈Each independently selected from C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7A cycloalkyl group. In embodiments, one or two R₈By C on one or more carbon atoms_1-3Alkyl substitution.

In embodiments, E isIn embodiments, E isOne or both of C and D being substituted by C on one or more carbon atoms_1-3Alkyl substitution, R₈Each independently selected from C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7A cycloalkyl group.

In embodiments, E isIn embodiments, E isOne or both of C and D being substituted by C on one or more carbon atoms_1-3Alkyl substituted, L is C_1-8Alkyl radical, C_1-8Perfluoroalkyl or C_3-7Cycloalkyl and unsubstituted or substituted on one or more carbon atoms by C_1-3Alkyl substitution, R₈Each independently selected from C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7A cycloalkyl group.

In embodiments, E isIn embodiments, E isWherein two R are₁₁Together include (═ O), and two R₁₁Containing methyl-CO₂R₁₂Wherein R is₁₂Is hydrogen such that E isIn embodiments, E isFor exampleOne or both of C and D being C on one or more carbon atoms_1-3Alkyl substitution, R₈Each independently selected from C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7A cycloalkyl group.

Examples of compounds of formula (II) according to the invention include:

1)2- ((2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((2- (dimethylamino) ethyl) amino)₄- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) amino) -2-oxoethyl) boronic acid; and

2) n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((2-dimethylamino) ethyl₄-1-methyl-1H-indol-3-yl) pyrimidinePyridin-2-yl) amino) phenyl) -2, 2-difluoro-3-oxobutanamide.

Another aspect of the disclosure provides an EGFR family tyrosine kinase inhibitor comprising a functional group that can bind to a serine residue in the C797S mutation of EGFR and/or the C805S mutation of HER2, wherein the EGFR family tyrosine kinase inhibitor comprises a compound of formula (III):

wherein

G is:

R₉each independently selected from hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, heteroaryl or together form a cycloalkyl;

m is selected from-CO₂NH₂、-CO₂NHR₁₀Alkyl, perfluoroalkyl, or cycloalkyl, optionally containing alkyl branches on one or more carbon atoms;

R₁₀including hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, or heteroaryl; and is

R₁₁Each independently selected from hydrogen, alkyl-CO₂R₁₂Or can form together (═ O), and R₁₂Selected from hydrogen or C_1-6An alkyl group.

In embodiments, R₉Each independently selected from C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7A cycloalkyl group. In embodiments, one or two R₉By C on one or more carbon atoms_1-3Alkyl substitution. In embodiments, M is C_1-8Alkyl radical, C_1-8Perfluoroalkyl or C_3-7Cycloalkyl radicals, M being unsubstituted or substituted on one or more carbon atoms by C_1-3Alkyl substitution.

In embodiments, R₉Are independently selected fromFrom C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7Cycloalkyl radical, each R₉Unsubstituted or substituted by C on one or more carbon atoms_1-3Alkyl substituted, M is C_1-8Alkyl or C_3-7Cycloalkyl radicals, M being unsubstituted or substituted on one or more carbon atoms by C_1-3Alkyl substitution.

In embodiments, G isIn embodiments, G isR₉Each independently selected from hydrogen and C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7Cycloalkyl, and each R₉By C being unsubstituted or by one or more carbon atoms_1-3Alkyl substitution.

In embodiments, G isIn embodiments, G isWherein two R are₁₁Together include (═ O), and two R₁₁Containing methyl-CO₂R₁₂Wherein R is₁₂Is hydrogen, such that G isIn embodiments, G isFor exampleR₉Each independently selected from hydrogen and C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7Cycloalkyl, and each R₉By C being unsubstituted or by one or more carbon atoms_1-3Alkyl substitution.

In embodiments, G isIn embodiments, G isR₉Each independently selected from C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7Cycloalkyl radical, each R₉Unsubstituted or substituted by C on one or more carbon atoms_1-3Alkyl substituted, M is C_1-8Alkyl or C_3-7Cycloalkyl radicals, M being unsubstituted or substituted on one or more carbon atoms by C_1-3Alkyl substitution.

The compounds of formula (I) of the present disclosure can be prepared, for example, by the procedures shown in reaction scheme (I) (see Bioorg. Med. chem. Lett., 2001; 11:1911 and International patent publication WO 2003/082831):

< reaction scheme (I) >

A, R therein₁、R₂、R₃、n_aAnd n_bHave the same meanings as defined above for the compounds of formula (I).

In reaction scheme (I), the compound of formula (X) is subjected to a condensation reaction with formamidine hydrochloride at an elevated temperature (210 ℃) to form an intermediate compound of formula (IX), which is then reacted with L-methionine in an organic acid, such as methanesulfonic acid, to induce removal of the methyl group at the C-6 position of the intermediate compound of formula (IX) to form an intermediate compound of formula (VIII).

Subsequently, the compound of intermediate (VIII) is subjected to a protective reaction in a base (e.g., pyridine) and anhydrous acetic acid to form the compound of intermediate (VII), and then reacted with an inorganic acid (e.g., thionyl chloride or phosphorus oxychloride) in the presence of a catalytic amount of dimethylformamide under reflux conditions to form the intermediate compound of formula (vi) in the form of a hydrochloride.

The compound of intermediate (VI) is added to an ammonia-containing alcoholic solution (e.g. 7N ammonia-containing methanol solution), which is stirred to induce removal of the acetyl group therefrom to form the compound of Intermediate (IV). Mitsunobu reaction of a compound of formula (IV) with a compound of formula (V) in an organic solvent such as 2-propanol or acetonitrile, and with R₁NH₂Carrying out substitution reaction to introduce R thereto₁. The resulting compound is reacted with an organic or inorganic acid (e.g., trifluoroacetic acid or heavy hydrochloric acid) in an organic solvent (e.g., dichloromethane) to induce removal of the t-butoxycarbonyl group, thereby forming an intermediate compound of formula (II). In the Mitsunobu reaction, diisopropyl azodicarboxylate, diethyl azodicarboxylate, di-tert-butyl azodicarboxylate or triphenylphosphine may be used.

The compounds of intermediate (I) of the present disclosure are then prepared by condensation reaction of the compound of formula (II) with the compound a-Cl of formula (III) in a mixture of organic solvents (e.g. tetrahydrofuran and water or dichloromethane) in the presence of an inorganic or organic base (e.g. sodium bicarbonate, pyridine or triethylamine) or by condensation reaction of the compound of intermediate (II) with the compound a-OH of intermediate (III) in an organic solvent (e.g. tetrahydrofuran or dichloromethane) in the presence of a coupling agent (e.g. 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide (EDC) or 2- (1H-7-azabenzotriazol-1-yl) -1,1,3, 3-tetramethylammonium Hexafluorophosphate (HATU)).

The compounds of formula (II) of the present disclosure can be prepared, for example, by the methods shown in the reaction schemes (IIA and IIB) (see j.med.chem.,2014,57(20), pp 8249-8267).

< reaction scheme (IIA) >

Wherein J, D and C have the same meaning as defined above for the compound of formula (II).

< reaction scheme (IIB) >

Wherein J, D and C have the same meaning as defined above for the compound of formula (II).

The difference between reaction scheme (IIA) and reaction scheme (IIB) is the addition of either indole (IIA) or pyrazolo [1,5-a ] pyridine (IIB) in step (i). In reaction scheme (II), 2, 4-dichloropyrimidine substituted with group J is reacted with MeMgBr (1 equivalent, 3.2M in 2-methyl THF) and 1 equivalent of indole or pyrazolo [1,5-a ] pyridine in THF at 0 deg.C and heated to 60 deg.C (i). In reaction scheme (IIA), 1.05 equivalents of sodium hydroxide and 1.05 equivalents of methyl iodide are added at 0 deg.C, replacing the hydrogen on the indole nitrogen with methyl (ii). 4-fluoro-5-nitroaniline (1.05 eq), toluene sulfonic acid (1.1 eq) and 2-pentanol were added to the mixture at 125 deg.C (iii). Subsequently, 2.2 equivalents of N (D) (C) portion were added to the DMA at 140 deg.C (iv), followed by 3 equivalents of iron, 0.7 equivalents of ammonium chloride, ethanol and water at 100 deg.C (v). E-Cl or E-OH (1M, THF, 1 equivalent) in DIPEA at 0 deg.C and THF were then added to incorporate a functional group that can bind serine, thereby forming the compound of formula (II).

The compounds of formula (III) of the present disclosure may be prepared, for example, by the procedures shown in reaction scheme (III) (see international patent application publication No. wo 2011/162515a 2).

< reaction scheme (III) >

Wherein G has the same meaning as defined above for the compound of formula (III).

In reaction scheme (III), the compound of formula 1 is subjected to a condensation reaction with urea in an organic solvent (e.g., N-dimethylformamide, N-dimethylacetamide, or N-methylpyrrolidone) at a temperature in the range of reflux temperature to 200 ℃; or with potassium cyanate at a temperature of room temperature to 100 deg.C under acidic conditions (e.g., 6% to 50% aqueous acetic acid) to provide the condensation compound of formula 2.

The resulting compound of formula 3 is refluxed with stirring in the presence of a chlorinating agent such as phosphorus oxychloride or thionyl chloride to give a chlorinated compound of formula 4, followed by a reaction in the presence of an inorganic base such as cesium carbonate, sodium carbonate or potassium carbonate in an organic solvent such as dimethyl sulfoxide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone, acetonitrile, tetrahydrofuran, 1, 4-dioxane, toluene or benzene at a temperature ranging from room temperature to 100 ℃ to induce the substitution of the C-4 position of the compound of formula 4 with the compound of formula 5 to give a compound of formula 6.

Reacting a compound of formula 6 with a compound of formula 7 in an alcohol solution (e.g., 2-propanol or 2-butanol) in the presence of an organic acid (e.g., trifluoroacetic acid (TFA)) at a temperature in the range of 70 ℃ to reflux temperature to provide a compound of formula 8.

Hydrogenation of the compound of formula 8 with a palladium/carbon catalyst, or reduction mediated with Fe, affords the aniline compound of formula 9. Subsequently, the aniline compound of formula 9 is reacted with a chloride of group G in an organic solvent (e.g., dichloromethane or tetrahydrofuran) or a mixed solvent (e.g., 50% aqueous tetrahydrofuran solution) in the presence of an inorganic base (e.g., sodium bicarbonate) or an organic base (e.g., triethylamine or diisopropylethylamine) at a low temperature ranging from-10 ℃ to 10 ℃; or using a coupling agent such as 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDCI) or 2- (1H-7-azabenzotriazol-1-yl) -1,1,3, 3-tetramethyluranium Hexafluorophosphate (HATU) together with the acid of the G group in pyridine to obtain a compound of formula 10 corresponding to the EGFR family tyrosine kinase inhibitor compound of formula (III).

The compounds of formulae (I) - (III) of the present disclosure may also be used in the form of pharmaceutically acceptable salts or solvates with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid.

The compounds of the present disclosure, or pharmaceutically acceptable salts or solvates thereof, selectively and effectively inhibit the growth of cancer cells induced by mutation of an activated epidermal growth factor family tyrosine kinase with cysteine to serine mutation, and provide enhanced anticancer effects when combined with another anticancer agent. That is, the compounds of the present disclosure, or pharmaceutically acceptable salts or solvates thereof, are useful for enhancing the effect of an anti-cancer agent selected from the group consisting of cell signaling inhibitors, mitotic inhibitors, alkylating agents, antimetabolites, antibiotics, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormonal agents, and anti-androgens.

Accordingly, the present disclosure provides a pharmaceutical composition for inhibiting the growth of cancer cells comprising one or more compounds of formula (I), formula (II), formula (III), pharmaceutically acceptable salts or solvates of the foregoing drugs or a combination thereof as an active ingredient and a method of treating a subject having an EGFR C797S mutation and/or a HER2C805S mutation comprising administering to the subject a pharmaceutically effective amount of an EGFR family tyrosine kinase inhibitor compound according to the present invention, or a pharmaceutically acceptable salt or solvate thereof.

For mammals, including single or divided doses of humans, an effective amount of the compound of the present invention or a pharmaceutically acceptable salt or solvate thereof may be administered orally or parenterally as an effective ingredient in an amount of about 0.01 to 100mg/kg body weight, preferably 0.2 to 50mg/kg body weight, per day. The dosage of the active ingredient can be adjusted according to various relevant factors, such as the condition of the subject to be treated, the type and severity of the disease, the administration rate and the doctor's opinion. In some cases, amounts less than the above-described dosages may be suitable. An amount greater than the above dosage may be used unless it causes harmful side effects, and the amount may be administered in divided doses per day.

The pharmaceutical compositions may be formulated according to any conventional method in the form of tablets, granules, powders, capsules, syrups, emulsions or microemulsions for oral administration or for parenteral administration, including intramuscular, intravenous and subcutaneous routes.

Pharmaceutical compositions for oral administration may be prepared by mixing the active ingredient with carriers such as cellulose, calcium silicate, corn starch, lactose, sucrose, glucose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifying agents, and diluents. Examples of carriers for use in the injectable compositions of the present disclosure are water, saline solutions, glucose-like solutions, alcohols, glycol ethers (e.g., polyethylene glycol 400), oils, fatty acids, fatty acid esters, glycerol esters, surfactants, suspending agents, and emulsifiers.

The following examples are intended to further illustrate the present disclosure without limiting its scope.

Examples

Example 1: preparation of intermediate Compounds of formula III

(1-1)6, 7-Dimethoxyquinazolin-4 (3H) -one

36.9g of 4, 5-dimethoxyanthranilic acid are mixed with 25.0g of formamidine hydrochloride and the mixture is stirred for 30 minutes at 210 ℃. After completion of the reaction, the solid thus obtained was cooled to room temperature, stirred with 200ml (0.33M) of an aqueous sodium hydroxide solution and filtered under reduced pressure. The solid thus obtained was washed with water and air-dried to obtain the title compound (24.6g, 64%).

¹H-NMR(300MHz,DMSO-d₆)7.99(s,1H),7.44(s,1H),7.13(s,1H),3.90(s,3H),3.87(s,3H).

(1-2) 6-hydroxy-7-methoxyquinazolin-4 (3H) -one

3.06g of the compound obtained in (1-1) was diluted with 20ml of methanesulfonic acid. 2.66g of L-methionine was added to the resulting solution, and stirred at 100 ℃ for 22 hours. Ice was added to the reaction mixture and neutralized with 40% aqueous sodium hydroxide solution to cause crystallization of the product. The solid was filtered under reduced pressure, washed with water, and air-dried to give the title compound (2.67g, 94%).

¹H-NMR(300MHz,DMSO-d₆)11.94(s,1H),9.81(s,1H),7.92(s,1H),7.39(s,1H),7.11(s,1H),3.91(s,3H).

(1-3) 7-methoxy-4-oxo-3, 4-dihydroquinazolin-6-yl acetate

6.08g of the compound obtained in (1-2) was dissolved in a mixture of 550ml of acetic acid and 7ml of pyridine, and the resulting solution was stirred at 100 ℃ for 3 hours. The reaction solution was cooled to room temperature, and ice was added thereto to cause crystallization of the product. The solid was filtered under reduced pressure, washed with water, and air-dried to give the title compound (4.87g, 65%).

¹H-NMR(300MHz,DMSO-d₆)12.21(s,1H),8.09(s,1H),7.76(s,1H),7.28(s,1H),3.91(s,3H),2.30(s,3H).

(1-4) 4-chloro-7-methoxyquinazolin-6-ylacetic acid hydrochloride

4.87g of the compound obtained in (1-3) was dissolved in a mixture of 33ml of thionyl chloride and 6ml of phosphorus oxychloride. Two drops of dimethylformamide were added to the resulting solution and stirred at 120 ℃ for 7 hours. The reaction solution was cooled to room temperature, and the solvent was removed therefrom under reduced pressure to obtain a residue. Toluene was added to the residue, and the resulting solution was concentrated under reduced pressure to remove the solvent, and the process was repeated two more times. The obtained solid was dried under reduced pressure to obtain the title compound (5.16 g).

¹H-NMR(300MHz,DMSO-d₆)9.01(s,1H),8.02(s,1H),7.64(s,1H),4.02(s,3H),2.35(s,3H).

(1-5) 4-chloro-7-methoxyquinazolin-6-ol

2g of the compound obtained in (1-4) was added to 25ml of a 7N ammonia methanol solution. The mixture was stirred at room temperature for 1 hour, and the solid formed in the reaction mixture was filtered, washed with ether, and dried to give the title compound (1.43g, 98%).

¹H-NMR(300MHz,DMSO-d₆)8.78(s,1H),7.41(s,1H),7.37(s,1H),₄.00(s,3H).

(1-6) N- (3, 4-dichloro-2-fluorophenyl) -7-methoxyquinazolin-6-yloxy) piperidin-1-yl) prop-2-en-1-one

1.43g of the compound obtained in (1-5), 1.91g of (R) - (-) -N-Boc-4-hydroxypiperidine and 1.96g of triphenylphosphine were added to 20ml of methylene chloride, and 2.01ml of diisopropyl azodicarboxylate was added dropwise thereto. The resulting mixture was stirred at room temperature for 1 hour and distilled under reduced pressure, and the residue was purified by column chromatography (ethyl acetate: dichloromethane: methanol ═ 20: 1) briefly. The partially purified residue was then dissolved in 60ml of 2-propanol, 1.17g of 3, 4-dichloro-4-fluoroaniline were added thereto, and the mixture was stirred at 100 ℃ for 3 hours. The resulting mixture was distilled under reduced pressure to remove the solvent, and the residue was dissolved in 60ml of dichloromethane. To this was added 60ml of trifluoroacetic acid, and the mixture was stirred at room temperature for 1 hour. The resulting mixture was distilled under reduced pressure to remove the solvent. A saturated sodium bicarbonate solution was added to the resulting residue to make it basic, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure. The obtained residue was subjected to column chromatography (chloroform: methanol ═ 1: 2) to obtain the title compound.

Example preparation of 21- (4- ((4- ((3, 4-dichloro-2-fluorophenyl) amino) -7-methoxyquinazolin-6-yl) oxy) piperidin-1-yl) -2, 2-difluorobutane-1, 3-dione

A portion of the compound (1mmol) obtained in (1-6) was mixed with benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop) (1.5 equivalents), triethylamine (3.0 equivalents), dichloromethane (30ml) and 2, 2-difluoro-3-oxobutanoic acid (1.3 equivalents) at room temperature, and stirring was continued for 12 hours.

Example preparation of 34- (4- ((4- (3, 4-dichloro-2-fluorophenyl) amino) -7-methoxyquinazolin-6-yl) oxy) piperidin-1-yl) -N,3, 3-trimethyl-2, 4-dioxobutanamide

A portion of the compound (1mmol) obtained in (1-6) was mixed with benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop) (1.5 equiv.), triethylamine (3.0 equiv.), dichloromethane (30ml) and 2, 2-dimethyl-4- (methylamino) -3, 4-dioxobutyric acid (1.3 equiv.) at room temperature and stirring was continued for 12 hours.

EXAMPLE 4 preparation of (2- (4- ((4- ((3, 4-dichloro-2-fluorophenyl) amino) -7-methoxyquinazolin-6-yl) oxy) piperidin-1-yl) -2-oxoethyl) boronic acid

A portion of the compound (1mmol) obtained in (1-6) was mixed with benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop) (1.5 equivalents), triethylamine (3.0 equivalents), dichloromethane (30ml) and 2- (di-t-butoxyboryl) acetic acid (1.3 equivalents) at room temperature, and stirring was continued for 12 hours. The mixture was then reacted with concentrated HCl.

Example 5 preparation of N1- (2-dimethylamino) ethyl) -N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine

2, 4-dichloropyrimidine was reacted with MeMgBr (1 equivalent, 3.2M in 2-methyl THF) and 1 equivalent of indole in THF at 0 deg.C and heated to 60 deg.C. At 0 deg.C, 1.05 equivalents of sodium hydroxide and 1.05 equivalents of methyl iodide are added, replacing the hydrogen on the indole nitrogen with a methyl group. 4-fluoro-5-nitroaniline (1.05 eq.), toluenesulfonic acid (1.1 eq.) and 2-pentanol were added to the mixture at 125 ℃. Subsequently, 2.2 equivalents of N, N, N' -trimethylethane-1, 2-diamine in DMA were added at 140 ℃ followed by 3 equivalents of iron, 0.7 equivalents of ammonium chloride, ethanol and water at 100 ℃ to give the compound of example 5.

Example 6 preparation of (2- ((2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-oxoethyl) boronic acid

A portion of the compound obtained in example 5 (1mmol) was combined with benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop) (1.5 equiv.), triethylamine (3.0 equiv.) and 2- (di-tert-butoxyborane) acetic acid (1.3 equiv.). The mixture was then reacted with concentrated HCl with stirring for 12 hours.

Example 7 preparation of N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) -2, 2-difluoro-3-oxobutanamide

A portion of the compound (1mmol) obtained in example 5 was stirred with benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBop) (1.5 equivalents), triethylamine (3.0 equivalents) and 2, 2-difluoro-3-oxobutanoic acid at room temperature for 12 hours.

Test example 1: inhibition of EGFR enzymes

Mu.l of EGFR (EGFR type 1 kinase, UPSTATE, 10 ng/. mu.l) was added to each well of the 96-well plate. As EGFR inhibitors, stepwise dilutions of 10 μ l serial dilutions of each compound obtained in examples 2 to 7 were added to each well and the plates were incubated at room temperature for 10 minutes. 10 μ l of Poly (Glu, Tyr) 4: 1(Sigma, 10ng/ml) and 10. mu.l ATP (50. mu.M) were added thereto to initiate a kinase reaction, and the resulting mixture was incubated at room temperature for 1 hour. To each well was added 10. mu.l of 100mM EDTA and stirred for 5 minutes to terminate the kinase reaction. To the reaction mixture were added 10. mu.l of 10X anti-phosphotyrosine antibody (Pan Vera), 10. mu.l of 10X PTK (protein tyrosine kinase) green tracer (Pan Vera) and 30. mu.l of FP (fluorescence polarization) dilution buffer, followed by incubation in the dark at room temperature for 30 minutes. FP values were determined for each well using a victoriiii fluorometer (Perkin Elmer) at 488nm (excitation filter) and 535nm (emission filter) and the IC50 for the concentration at which 50% inhibition was observed was determined, with the maximum (0% inhibition) value set to the polarized light value measured for wells not treated with EGFR inhibitor and the minimum value corresponding to 100% inhibition. The calculation and analysis of IC50 was performed using Microsoft Excel.

Test example 2: inhibition of EGFR mutase (C797S)

The procedure of test example 1 was repeated except that 10. mu.l of C797S enzyme (EGFR C797S kinase, UPSTATE) was used instead of 10. mu.l of EGFR.

Test example 3: cancer cell growth inhibition assay

Lung and breast cancer cell lines with EGFR C797S mutation or HER2C805S mutation were used to test the efficacy of the compounds of the present invention in inhibiting the growth of cancer cells (fetal bovine serum) using DMEM (Dulbecco's modified Eagle's Medium) Medium supplemented with 4.5g/1 glucose and 1.5g/1 sodium bicarbonate and with 10% FBS.

Cancer cell lines stored in liquid nitrogen tanks were each rapidly thawed at 37 ℃ and centrifuged to remove the medium. Mixing the obtained cell precipitate with culture medium, and culturing at 37 deg.C with 5% CO₂The lower flask was incubated for 2 to 3 days, and the medium was removed. The remaining cells were washed with DPBS (Dulbecco's phosphate buffered saline) and isolated from the flask using Tripsin-EDTA. The isolated cells were diluted with medium to a concentration of 100,000 cells/ml. 100 μ l of the diluted cell suspension was added to each well of a 96-well plate and incubated at 37 ℃ with 5% CO₂The following incubation took 1 day.

The compounds obtained in examples 2 to 7 and the conventional EGFR inhibitors Iressa and lapatinib as positive controls and afatinib, poziotinib and Oxicitinib as negative controls were dissolved in 99.5% DMSO, respectively, at a concentration of 25 mM. If the test compound is not soluble in DMSO, a small amount of 1% HCl is added and treated in a water bath at 40 ℃ for 30 minutes until complete dissolution. Test compound solutions were diluted with culture medium to a final concentration of 100 μ M and then serially diluted 10-fold to 10-6 μ M (final concentration of DMSO less than 1%). Media was removed from each well of a 96-well plate.

Mu.l of test compound solution was added to each well containing cultured cells and the plates were incubated at 37 ℃ in 5% CO₂Incubate for 72 hours. After removing the medium from the plate, 50. mu.l of 10% trichloroacetic acid was added to each well, and the plate was maintained at 4 ℃ for 1 hour to fix the cells on the bottom of the plate. Removing from each wellTrichloroacetic acid was added, the plate was dried, 100. mu.l of an SRB (sulforhodamine-B) dye solution was added thereto, and the resulting mixture was allowed to react for 10 minutes. An SRB dye solution was prepared by dissolving SRB in 1% acetic acid to a concentration of 0.4%. After removal of the dye solution, the plate was washed with water and dried. When the dye solution could not be effectively removed with water, 1% acetic acid was used. To each well 150. mu.l of 10mM Tris-base was added and the absorbance at 540nm was measured with a microplate reader.

The IC50 at which 50% inhibition occurred was assessed based on the difference (considered as 100%) between the final concentration of test cells and the initial concentration of cells incubated in wells not treated with test compound. The calculation of IC50 was performed by using microsoft excel.

Test example 4: prolonged study

Lung cancer cell lines with EGFR C797S mutation were used to test the ability of the compounds of the invention to inhibit EGFR phosphorylation and to inhibit prolongation of its phosphorylation ability.

Cell lines were incubated in culture flasks at 37 ℃ in 95% air and 5% CO2 using medium containing DMEM, 10% FBS and 1% PS. When more than 90% of the total volume of the flask was filled with cells, the cultured cell suspension was subjected to secondary culture and then poured into each well of a 6-well plate in an amount of 500,000 cells/well. After 24 hours, cells were separated from the solution, washed with PBS, and incubated in media containing DMEM, 0.1% FBS, and 1% PS for 16 hours. The compounds obtained in examples 2 to 7 and Tarceva (Tarceva) as an EGFR phosphorylation inhibitor were each added to a cell-containing well at a concentration of 1 μ M. After 4 hours, cells were isolated from the solution, washed 4 times with PBS after 0,2, 4 and 8 hours, and incubated in media containing DMEM, 0.1% FBS and 1% PS. When 0, 8, 24 and 48 hours have passed after the washing, respectively, the medium was removed therefrom to terminate the reaction. Immediately before completion of the reaction, the cultured cell solution was treated with EGF (Sigma, catalog No. E99644) at a concentration of 100ng/ml for 5 minutes to induce activation of EGFR. After the reaction was completed, the well plate in which the cultured cells were stored was stored at-70 ℃. In the control group, replacement of the medium was performed instead of adding an EGFR phosphorylation inhibitor, in which EGF was used to induce EGFR activation only in the positive control group, but not in the negative control group.

For Western blot and enzyme immunoassay (ELISA) methods, the well plates stored at-70 ℃ were thawed to room temperature and then protein was extracted from the cells in the well plates using protein extraction buffer. The protein extraction steps are as follows: 250 μ l of protein extraction buffer (phosphate safety extraction reagent, Calbiochem, Cat. No. 71296-3) containing protease inhibitor cocktail was added to each cell-containing well and stirred at room temperature for 5 minutes. Cells were harvested using a cell scraper and placed in a 1.5ml tube, which was centrifuged at 16,000x g for 5 minutes. The thus obtained upper layer was separated, and the protein content therein was determined by means of a protein assay kit (Bio-rad, catalog No. 500-0116). The extracted protein was diluted with PBS to a concentration of 0.8 mg/ml.

Human EGFR (py1173) immunoassay kit (Biosource, catalog No. KHR9071) was used in the enzyme immunoassay method. 100 μ l of a 4-fold diluted sample with standard dilution buffer in the kit was added to the paper wells and incubated overnight in a refrigerator at 4 ℃. Cultured cells were isolated therefrom and washed 4 times with 200. mu.l of washing buffer. Mu.l of primary antibody (rabbit anti-human EGFR [ pY1173]) was placed in each strip well, incubated at 37 ℃ for 1 hour, and washed 4 times with 200. mu.l of washing buffer. The secondary antibody (anti-rabbit IgG-HRP) was diluted 100-fold with HRP dilution buffer in the kit. Mu.l of the dilution was placed in each well of the paper, incubated at 37 ℃ for 30 minutes and then washed 4 times with 200. mu.l of wash buffer. Mu.l HRP substrate in the kit was placed in each strip well and incubated in the dark for 10 to 30 minutes. To this was added 100. mu.l of a reaction termination solution to terminate the reaction, and then absorbance at 450nm was observed.

Electrophoresis and western blotting were performed based on the following general methods: LDS buffer was added to each sample, which was boiled at 70 ℃ for 10 minutes. Mu.l of the resulting solution was applied to a 12-well gel (Nupage 4-12% Bis-tris gel, Invitrogen), and subjected to 120V electrophoresis in a buffer (MOPS electrophoresis buffer, Invitrogen, catalog No. NP0006-1) for 2 hours. After electrophoresis, the resulting protein bands were transferred to nitrocellulose membrane (Bio-rad, Cat. No. 162-0251) for 2 hours in 30V transfer buffer (Invitrogen, Cat. No. NP 0001). The transferred nitrocellulose membrane was allowed to react with 3% BSA blocking solution at room temperature for 1-2 hours to suppress nonspecific antigen-antibody reaction. Primary antibodies diluted with blocking solution (anti-EGFR (Stressgen, Cat. No. CSA330, 1: 100 dilution)), anti-pEGFR (Santacruz, Cat. No. SC12351-R, 1: 500 dilution) and anti-beta actin (Sigma, Cat. No. A1978, dilution 4. mu.g/ml) were reacted with each other at 4 ℃ overnight and then washed 4 times with washing buffer (TBS-T) every 10 minutes. Secondary antibodies (anti-mouse IgG (Chemicon, cat No. AP124P, 1: 5000 dilution)) and anti-rabbit IgG (Chemicon, cat No. AP132P, 1: 5000 dilution) diluted with blocking solution were reacted with each other at room temperature for 1 hour, then washed 5 times with washing buffer every 10 minutes, then stained with ECL immunoblot detection reagent (Amersham, cat No. RPN2209), and revealed to Hyperfilm (Amersham, cat No. RPN2103K) in a dark room. Protein bands were observed by development of the membrane.

Compared to conventional irreversible EGFR inhibitors, i.e., bosutinib, ocitinib and afatinib, the compounds of the present disclosure show superior anticancer activity by effectively inhibiting the activity of EGFR C797S mutant kinase and the growth of cell lines having mutations. The compounds of the present disclosure exhibit highly improved inhibitory activity against cell lines having EGFR C797S mutation or HER2C805S mutation, while none of the compounds of the present disclosure inhibit the growth of enzymes of cell lines that do not have C797S or C805S mutations. Such a result is the effect of reacting with the serine residue of the compounds of the present invention relative to conventional irreversible EGFR inhibitors that do not react with serine. Conventional reversible inhibitors inhibit enzymes and cell lines with mutations, but are much less potent than the compounds of the present disclosure.

Test example 5: inhibition of the HER2 enzyme

Mu.l of HER2(HER2 kinase, ACRO Biosystems, 10 ng/. mu.l) was added to each well of a 96-well plate. As HER2 inhibitor, 10 μ l serial dilution solutions of each compound obtained in examples 2 to 7 were sequentially added to each well, and iressa (Astrazeneca) and lapatinib (GlaxoSmithKline) were added to each well, and the plates were incubated at room temperature for 10 minutes. 10 μ l of Poly (Glu, Tyr) 4: 1(Sigma, 10ng/ml) and 10. mu.l ATP (50. mu.M) were added thereto to initiate a kinase reaction, and the resulting mixture was incubated at room temperature for 1 hour. To each well was added 10. mu.l of 100mM EDTA and stirred for 5 minutes to terminate the kinase reaction. To the reaction mixture were added 10. mu.l of 10X anti-phosphotyrosine antibody (PanVera), 10. mu.l of 10X PTK (protein tyrosine kinase) green tracer (Pan Vera) and 30. mu.l of FP (fluorescence polarization) dilution buffer, followed by incubation in the dark at room temperature for 30 minutes. FP values were determined for each well using a victoriiii fluorometer (Perkin Elmer) at 488nm (excitation filter) and 535nm (emission filter) and the IC50 for the concentration at which 50% inhibition was observed was determined, with the maximum (0% inhibition) value set to the polarized light value measured for wells not treated with HER2 inhibitor and the minimum value corresponding to 100% inhibition. The calculation and analysis of IC50 was performed using Microsoft Excel.

Test example 6: inhibition of HER2 mutant enzyme (C805S)

The procedure of test example 5 was repeated except that 10. mu.l of C805S enzyme (HER 2C805S kinase) was used instead of 10. mu.l of HER 2.

The foregoing description is given for clearness of understanding only, and no unnecessary limitations should be understood therefrom, as modifications within the scope of the invention may be apparent to those having ordinary skill in the art.

All patents, publications, and references cited herein are incorporated by reference in their entirety. In the event of a conflict between the present disclosure and an incorporated patent, publication, or reference, the present disclosure controls.

Claims (38)

1. An Epidermal Growth Factor Receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group capable of binding to serine S797 residue in EGFR with a C797S mutation or serine S805 residue in HER2 with a C805S mutation.

2. The EGFR family tyrosine kinase inhibitor of claim 1, comprising a compound of formula (I):

wherein

A is

R₄Each independently is hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, heteroaryl, or together form a cycloalkyl;

R₅is-NHR₆、-C(O)R₇Alkyl, cycloalkyl, perfluoroalkyl, aryl or heteroaryl;

R₆is hydrogen, alkyl, cycloalkyl, perhaloalkyl, aryl or heteroaryl;

and R is₇Is NHR₆Hydrogen, alkyl, cycloalkyl, perhaloalkyl, aryl or heteroaryl;

R₁₁each independently selected from hydrogen, alkyl-CO₂R₁₂Or can form together (═ O), and R₁₂Selected from hydrogen or C_1-6An alkyl group;

R₁is C substituted by 1 to 5X_6-10Aryl, 5-to 10-membered heterocyclic group having at least one selected from N, O and S and substituted with 1 to 5X, or C substituted with phenyl_1-6An alkyl group;

R₂is hydrogen, hydroxy, C_1-6Alkoxy or by C_1-6Alkoxy or C substituted with at least one 5-or 6-membered heterocyclyl selected from N, O and S_1-6An alkoxy group;

R₃is hydrogen, -COOH, C_1-6Alkoxycarbonyl, N-unsubstituted or N-acylamino substituted by Y;

n_aand n_bAre all integers from 0 to 6, with the proviso that n_aAnd n_bNot simultaneously 0, and when n_aIs 0, saidIs that

And when n is_bIs 0, saidIs that

Wherein

X is hydrogen, halogen, hydroxy, cyano, nitro, (mono-, di-or trihalo) methyl, mercapto, C_1-6Alkylthio, acrylamido, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Alkoxy, aryloxy, C_1-6Dialkylamino, C substituted by Z_1-6Alkyl or C substituted by Z_1-6An alkoxy group;

y is hydroxy, or C_1-6Alkyl, or C substituted by Z_1-6An alkyl group; and

z is hydroxy, C_1-3Alkoxy radical, C_1-3Alkylthio radical, C_1-3Alkylsulfonyl, di-C_1-3Alkylamine, C_1-6Alkyl, aryl, or 5-or 6-membered aromatic or non-aromatic heterocyclic group containing 1 to 4 members selected from N, O, S, SO and SO₂And said aryl and heterocyclyl are unsubstituted or selected from halogen, hydroxy, amino, nitro, cyano, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Alkoxy radical, C_1-6Monoalkylamino and C_1-6A substituent of a dialkylamino group.

3. The EGFR family tyrosine kinase inhibitor of claim 2, wherein R₆Is C_1-6Alkyl or C_3-7A cycloalkyl group.

4. The EGFR family tyrosine kinase inhibitor of claim 2 or 3, wherein R₇Is C_1-6Alkyl or C_3-7A cycloalkyl group.

5. The EGFR family tyrosine kinase inhibitor of any one of claims 2 to 4, wherein R₁Is C substituted by 3X₆-an aryl group.

6. The EGFR family tyrosine kinase inhibitor of any one of claims 2 to 5, wherein n_aAnd n_bAre both 2.

7. The EGFR family tyrosine kinase inhibitor of any one of claims 2 to 6, wherein R₂Is methoxy.

8. The EGFR family tyrosine kinase inhibitor of any one of claims 2 to 7, wherein R₃Is hydrogen.

9. The EGFR family tyrosine kinase inhibitor of any one of claims 2 to 8, wherein A

Is thatAnd R is₄Are each individually halogen.

10. The EGFR family tyrosine kinase inhibitor of claim 9, wherein each R is₄Is fluorine.

11. The EGFR family tyrosine kinase inhibitor of any of claims 2 to 10, wherein a

Is thatR₅is-C (O) R₇And R is₇Is NHR₆。

12. The EGFR family tyrosine kinase inhibitor of any one of claims 2 to 8, wherein A

Is thatAnd R is₄Each independently of the others is hydrogen, halogen, C_1-6Alkyl radical, C_3-7Cycloalkyl, perfluoroalkyl, cycloalkyl, aryl, heteroaryl or together form C_3-7A cycloalkyl group.

13. The EGFR family tyrosine kinase inhibitor of any one of claims 2 to 8, wherein A

Is thatAnd R is₄Each independently of the others is hydrogen, halogen, C_1-6Alkyl radical, C_3-7Cycloalkyl, perfluoroalkyl, cycloalkyl, aryl, heteroaryl or together form C_3-7A cycloalkyl group.

14. The EGFR family tyrosine kinase inhibitor of claim 1 or 2, selected from the group consisting of:

1)4- (4- ((4- (3, 4-dichloro-2-fluorophenyl) amino) -7-methoxyquinazolin-6-yl) oxy) piperidin-1-yl) -N,3, 3-trimethyl-2, 4-dioxobutanamide;

2) (2- (4- ((4- ((3, 4-dichloro-2-fluorophenyl) amino) -7-methoxyquinazolin-6-yl) oxy) piperidin-1-yl) -2-oxoethyl) boronic acid; and

3)1- (4- ((4- ((3, 4-dichloro-2-fluorophenyl) amino) -7-methoxyquinazolin-6-yl) oxy) piperidin-1-yl) -2, 2-difluorobutane-1, 3-dione.

15. The EGFR family tyrosine kinase inhibitor of claim 1, comprising a compound of formula (II):

wherein the content of the first and second substances,

a is

E is

J comprises-CO₂R₁₀Halogen, NHC (O) R₁₀；

R₈Each independently selected from hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, heteroaryl or together form a cycloalkyl;

R₁₀including hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, or heteroaryl;

R₁₁each independently selected from hydrogen, alkyl-CO₂R₁₂Or can form together (═ O), and R₁₂Selected from hydrogen or C_1-6An alkyl group;

c and D are each independently selected from alkyl, -N (R)₈)₂、-OR₈alkyl-W or together can comprise cycloalkyl;

w is selected from-N (R)₈)₂OR-OR₈(ii) a And

l is selected from-CO₂NH₂、-CO₂NHR₁₀Alkyl, perfluoroalkyl, or cycloalkyl.

16. The EGFR family tyrosine kinase inhibitor of claim 15, wherein one or both of C and D is C_1-6Alkyl or together containing C_3-7A cycloalkyl group.

17. The EGFR family tyrosine kinase inhibitor of claim 15 or 16, wherein one or both of C and D are C-substituted on one or more carbon atoms_1-3Alkyl substitution.

18. The EGFR family tyrosine kinase inhibitor of any of claims 15-17, wherein R₈Each independently selected from C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7A cycloalkyl group.

19. The EGFR family tyrosine kinase inhibitor of any of claims 15-18, wherein one or both R8 is C-bonded at one or more carbon atoms_1-3Alkyl substitution.

20. The EGFR family tyrosine kinase inhibitor of any of claims 15-19, wherein L is C_1-8Alkyl radical, C_1-8Perfluoroalkyl or C_3-7Cycloalkyl, and unsubstituted or substituted on one or more carbon atoms by C_1-3Alkyl substitution.

21. The EGFR family tyrosine kinase inhibitor of any of claims 15-19, wherein

E is

22. The EGFR family tyrosine kinase inhibitor of any of claims 15-20, wherein

E is

23. The EGFR family tyrosine kinase inhibitor of any of claims 15-19, wherein

E is

24. According toThe EGFR family tyrosine kinase inhibitor of any of claims 15-23, wherein J comprises-CO₂R₁₀。

25. The EGFR family tyrosine kinase inhibitor of any one of claims 15-23, wherein J comprises-nhc (o) R₁₀。

26. The EGFR family tyrosine kinase inhibitor of claim 24 or 25, wherein R is₁₀Comprises C_1-6Alkyl or C_3-7A cycloalkyl group.

27. The EGFR family tyrosine kinase inhibitor of any of claims 15-23, wherein J is chloro.

28. The EGFR family tyrosine kinase inhibitor of claim 15, selected from the group consisting of:

1) (2- ((2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) amino) -2-oxoethyl) boronic acid; and

2) n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) -2, 2-difluoro-3-oxobutanamide.

29. The EGFR family tyrosine kinase inhibitor of claim 1, comprising a compound of formula (III):

wherein

G is:

R₉each independently selected from hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, heteroarylOr together form a cycloalkyl group;

m is selected from-CO₂NH₂、-CO₂NHR₁₀Alkyl, perfluoroalkyl, or cycloalkyl, optionally containing alkyl branches on one or more carbon atoms;

R₁₀including hydrogen, halogen, alkyl, cycloalkyl, perfluoroalkyl, aryl, or heteroaryl; and

R₁₁each independently selected from hydrogen, alkyl-CO₂R₁₂Or can form together (═ O), and R₁₂Selected from hydrogen or C_1-6An alkyl group.

30. The EGFR family tyrosine kinase inhibitor of claim 29, wherein each R9 is independently selected from C_1-6Alkyl radical, C_3-7Cycloalkyl radicals or taken together to form C_3-7A cycloalkyl group.

31. The EGFR family tyrosine kinase inhibitor of claim 29 or 30, wherein one or both R9 is C-substituted at one or more carbon atoms_1-3Alkyl substitution.

32. The EGFR family tyrosine kinase inhibitor of any of claims 29-31, wherein M is C_1-8Alkyl radical, C_1-8Perfluoroalkyl or C_3-7Cycloalkyl, and unsubstituted or substituted on one or more carbon atoms by C_1-3Alkyl substitution.

33. The EGFR family tyrosine kinase inhibitor of any of claims 29-31, wherein G is

34. The EGFR family tyrosine kinase inhibitor of any of claims 29-31, wherein

G is

35. The EGFR family tyrosine kinase inhibitor of any of claims 29-32, wherein

G is

36. A pharmaceutical composition comprising the EGFR family tyrosine kinase inhibitor compound of any one of claims 2 to 35, or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient, and a pharmaceutically acceptable carrier.

37. A method of treating a subject having an EGFR C797S mutation, comprising administering to the subject a pharmaceutically effective amount of an EGFR family tyrosine kinase inhibitor compound, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 35.

38. A method of treating a subject having a HER2C805S mutation, the method comprising administering to the subject a pharmaceutically effective amount of an EGFR family tyrosine kinase inhibitor compound of any one of claims 1-35, or a pharmaceutically acceptable salt or solvate thereof.